InvestorNewsBreaks – Healthtech Solutions Inc. (HLTT) Announces Strategic CEO Appointment

May 17, 2021 10:03:50
Healthtech Solutions (OTC: HLTT), the parent company of Varian Biopharmaceuticals Inc., Medi-Scan Inc. and RevHeart Inc., has announced its appointment of Edward (“Ned”) Swanson, M.D., as its chief executive officer. Dr. Swanson brings a unique background and skillset that is particularly well suited to lead Healthtech, combining scientific, clinical and industry knowledge. He is a co-founder of PolarityTE Inc., a biotech company developing various regenerative tissue products and biomaterials, led by its flagship product SkinTE(R). In his leadership roles with PolarityTE and its subsidiaries, Dr. Swanson gleaned deep industry knowledge and know-how related to company formation, financing, product development, medical and regulatory affairs, manufacturing, business development, and commercialization within health care. “With Ned Swanson at the helm of Healthtech Solutions, we have the leadership and expertise of an individual who has demonstrated success at both medical bioengineering and effective public company stewardship at C-level,” said Healthtech Solutions Chairman David Rubin. “His direction will facilitate a rise to a new level for the company and serve to deliver continued growth and shareholder value.” To view the full press release, visit About Healthtech Solutions Inc. Healthtech Solutions is a reporting public company. The board of directors is focusing the company’s resources into creating a platform to acquire and/or invest in cutting-edge health care technology in the medical device biopharma and pharmaceutical fields. The goal is to bring these solutions to market. To date, Healthtech Solutions has invested in three areas of medical technology breakthrough:
  • Medi-Scan Inc., which is developing a technology that converts 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can provide the data equivalent to an X-ray, MRI or CT scan, without radiation and at a lower cost.
  • RevHeart Inc., which is advancing critical research into the treatment of COVID-related heart muscle injury.
  • Varian Biopharmaceuticals Inc., a precision oncology company, is the first acquisition of Healthtech Oncology Inc.
Healthtech Solutions has a pipeline of additional acquisitions currently under due diligence. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.